Can nevirapine be safely substituted for other agents in those with high CD4 cell counts and virologic suppression?

HIV Treatment Bulletin - Vol. 8, No. 8/9, August-September 2007

Michael Dube, for NATAP.org

This question was addressed by the observational Dutch cohort study ATHENA, presented by Ferdinand Wit. The concern of course is when nevirapine is started in ART-naïve patients with high CD4 cell counts (>250 females, >400 males) there is excessive hepatotoxicity which can be severe. But does this carry over to individuals who are already virologically suppressed, and are switched to nevirapine?

One published study from the EuroSida cohort (Antiviral Therapy 12:335, 2007) showed that switching to nevirapine with high CD4 cell counts was significantly safer in ART-experienced patients than in ART-naïves. This was particularly true during the first 3 months of therapy.

The presentation from ATHENA reached similar conclusions. Those with low CD4 cell counts when ART was initiated, but who had high CD4 counts at the time of switching, tolerated the switch to nevirapine as well as ART-naïve subjects with low CD4 counts whose initial therapy included nevirapine.

These observational data provide some additional comfort to those patients with virologic suppression and now have high CD4 counts who are considering a switch to nevirapine. It is possible though, that some of the hypersensitivity reactions seen in the ART-naïve patients are due to newly started medications other than nevirapine, so that these reactions may be relatively over-reported and attributed to nevirapine.

Said otherwise, ART-experienced patients who switch may actually have higher rates of nevirapine reactions - but since they may only be starting one new drug, this is not confounded by their other medications and only “true” nevirapine reactions get counted.

A switch to nevirapine should still be always considered potentially risky and be monitored closely, until a randomised controlled trial more definitively establishes the safety of this sort of switch approach.

Comment

It should be added that these patients had undetectable viral load at the time of the switch.

No information was provided about the choice of dosing, and whether patients switched to the full nevirapine dose or whether they use the 200mg once-daily dose for the first two weeks. There is still no clear evidence to inform this decision.

Ref: Wit F et al. Incidence of hypersensitivity reactions associated with nevirapine-containing HAART in patients with prior treatment experience may differ from that in treatment-naïve patients: the ATHENA cohort study.

2007-08-10
IB070808-22

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.